Welcome to our dedicated page for Xylem SEC filings (Ticker: XYL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Xylem Inc. filings document the regulatory disclosures of a public operating company focused on water solutions and resource management. Recent Form 8-K reports furnish quarterly and annual financial results, including press-release exhibits for orders, revenue, earnings measures and guidance-related disclosures.
Other Xylem filings record capital actions such as common-stock repurchase authorization, while definitive proxy materials cover governance, shareholder voting matters and executive compensation disclosures, including equity-award and pay-versus-performance information.
Geri-Michelle McShane, Vice President and Chief Accounting Officer of Xylem Inc. (XYL), reported a sale of 1,000 shares of Xylem common stock on 09/05/2025 at a weighted-average price of $139.962 per share (executed in a price range of $139.96–$139.98). After the transaction, the reporting person beneficially owned 2,957 shares of Xylem common stock. The Form 4 was signed by a power of attorney on behalf of the reporting person.
Xylem Inc. (XYL) Form 144 notifies a proposed sale of 1,000 common shares through Morgan Stanley Smith Barney on the NYSE with an aggregate market value of $139,962. The filing lists the issuer's outstanding common shares as 243,409,688, and shows an approximate sale date of 09/05/2025. The shares reported were acquired primarily via the company's Employee Stock Purchase Plan in multiple small purchases between 03/23/2023 and 03/01/2024, with the largest single acquisition entries totaling 477, 322, and 136 shares.
The notice contains no reportable sales in the past three months and includes the standard representation that the seller is unaware of undisclosed material adverse information about the issuer.
Stacy Cozad, SVP & Chief Legal Officer of Xylem Inc. (XYL), received equity awards on 09/02/2025. The filing reports 735 restricted stock units granted at an indicated price of $140.35 and 2,579 non-qualified stock options$140.35. The RSUs and options vest in three equal annual tranches on March 5, 2026, 2027 and 2028. After these transactions the filing shows 735 shares2,579 option-related shares
Insider sale by Xylem director. A director of Xylem Inc. reported selling 4,900 shares of the company's common stock on 08/18/2025 at a weighted average price of $140.6594 per share. After the sale the reporting person beneficially owns 5,163 shares. The filing discloses that the 4,900 shares were sold across a price range of $140.43 to $140.86 and that the reporting person will provide details of the number of shares sold at each price upon request.
Form 144 filed for Xylem Inc. (XYL) reporting a proposed sale of 4,900 shares of common stock through Goldman Sachs & Co. LLC on 08/18/2025. The filing lists an aggregate market value of $690,165 and indicates 243,409,688 shares outstanding for the issuer. The shares to be sold were acquired as restricted stock units (compensation) on multiple dates between 02/16/2023 and 05/12/2025, in lots of 915, 1187, 1633, 3, 7 and 1155 shares respectively. The filer attests they are not aware of undisclosed material adverse information about the issuer. No sales in the past three months were reported.
Stacy Cozad, serving as SVP & Chief Legal Officer and an officer/director of Xylem Inc. (XYL), filed an Initial Form 3 reporting the event dated 08/13/2025. The filing states no securities are beneficially owned by the reporting person as of the filing date. The form was signed by an attorney-in-fact and confirms compliance with Section 16 reporting requirements.
XYL Q2-25 showed solid top-line and earnings momentum. Revenue rose 6.1% YoY to $2.30 bn, driven by mid-single-digit growth across all four segments, with Measurement & Control Solutions up 14%. Gross margin expanded 100 bp to 38.8%, lifting operating income 21% to $305 m. Net income attributable to Xylem increased 16% to $226 m; diluted EPS reached $0.93 versus $0.80.
First-half trends were similarly positive. 1H-25 revenue grew 4% to $4.37 bn and EPS climbed 13% to $1.62. Operating cash flow slipped 10% to $338 m as working-capital needs rose, but cash on hand still improved to $1.17 bn. Net debt fell $20 m to $826 m as the company repaid $28 m of long-term borrowings.
Portfolio actions continue. Xylem completed two tuck-in deals—Vacom Systems ($42 m) and Simply Clean ($7 m)—and exited the Evoqua Magneto unit, booking a $10 m loss. Restructuring/impairment charges totaled $47 m YTD, mainly for severance and software write-offs. Goodwill now stands at $8.24 bn after 2024’s Idrica step-up.